Evidence map›Paper›PMID 31254120›Full record

ArticleBrain informatics2019

Predicting the course of Alzheimer's progression.

Samuel Iddi, Dan Li, Paul S Aisen, Michael S Rafii, Wesley K Thompson, Michael C Donohue, Alzheimer’s Disease Neuroimaging Initiative

Abstract read
In one paragraph

Article in Brain informatics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Cross-dataset Evaluation of Dementia Longitudinal Progression Prediction Models.medRxiv : the preprint server for health sciences · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Predicting clinical progression trajectories of early Alzheimer's disease patients.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Multimodal attention-based deep learning for Alzheimer's disease diagnosis.Journal of the American Medical Informatics Association : JAMIA · 2022
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Samuel IddiAlzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, USA.ORCID http://orcid.org/0000-0002-2366-2774
Dan LiAlzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, USA.
Paul S AisenAlzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, USA.
Michael S RafiiAlzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, USA.
Wesley K ThompsonDepartment of Family Medicine and Public Health, University of California, San Diego, USA.
Michael C DonohueAlzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, USA. mdonohue@usc.edu.
Alzheimer’s Disease Neuroimaging Initiative

Funding

Estimating Long-Term Disease Trajectories from Short-Term DataR01AG049750 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI DONOHUE, MICHAEL C · 2016 to 2019
$1.6M
Biomarkers Across Neurodegenerative Disease BAND-14-338179NIA NIH HHS R01 AG049750NIA NIH HHS R01-AG049750
6 · The paper itself

Abstract

Alzheimer's disease is the most common neurodegenerative disease and is characterized by the accumulation of amyloid-beta peptides leading to the formation of plaques and tau protein tangles in brain. These neuropathological features precede cognitive impairment and Alzheimer's dementia by many years. To better understand and predict the course of disease from early-stage asymptomatic to late-stage dementia, it is critical to study the patterns of progression of multiple markers. In particular, we aim to predict the likely future course of progression for individuals given only a single observation of their markers. Improved individual-level prediction may lead to improved clinical care and clinical trials. We propose a two-stage approach to modeling and predicting measures of cognition, function, brain imaging, fluid biomarkers, and diagnosis of individuals using multiple domains simultaneously. In the first stage, joint (or multivariate) mixed-effects models are used to simultaneously model multiple markers over time. In the second stage, random forests are used to predict categorical diagnoses (cognitively normal, mild cognitive impairment, or dementia) from predictions of continuous markers based on the first-stage model. The combination of the two models allows one to leverage their key strengths in order to obtain improved accuracy. We characterize the predictive accuracy of this two-stage approach using data from the Alzheimer's Disease Neuroimaging Initiative. The two-stage approach using a single joint mixed-effects model for all continuous outcomes yields better diagnostic classification accuracy compared to using separate univariate mixed-effects models for each of the continuous outcomes. Overall prediction accuracy above 80% was achieved over a period of 2.5 years. The results further indicate that overall accuracy is improved when markers from multiple assessment domains, such as cognition, function, and brain imaging, are used in the prediction algorithm as compared to the use of markers from a single domain only.

Indexed as

Alzheimer’s diseaseBiomakersClassification Clinical diagnosisDisease trajectoriesJoint mixed-effects modelsLatent time shiftModel averagingMulti-cohort longitudinal dataMulti-level Bayesian modelsPredictionsRandom forest

Identifiers

PMID31254120
PMCPMC6598897

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.